Otonomy, Inc (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, announced multiple presentations at the upcoming Association for Research in Otolaryngology (ARO) 42nd Annual MidWinter Meeting, to be held February 9-13, in Baltimore.
“Our multiple presentations at ARO demonstrate our broad pipeline in neurotology with data presented in support of our product candidates for Ménière’s disease, tinnitus, hearing loss, and otoprotection,” said Kathie Bishop, PhD, chief scientific officer of Otonomy. “In particular, we are pleased to present information on our clinical program for OTO-313, including the Phase 1/2 clinical trial in tinnitus patients to be initiated next quarter, and preclinical data related to our OTO-510 program for otoprotection that will initially focus on the prevention of cisplatin-induced hearing loss (CIHL) in children.”
Otonomy’s presentation related to the OTO-313 program for tinnitus is as follows:
- “Clinical development of intratympanic, sustained-exposure formulation of the NMDA receptor antagonist gacyclidine for the treatment of tinnitus” by Anderson et al, podium presentation on February 13 at 12:15 pm EST.
Presentations related to the OTO-510 program for CIHL include:
- “Characterization of in-vivo rodent models of cisplatin-induced hearing loss—acute and chronic administration paradigms” by Piu et al, poster presentation on February 9 beginning at 1 pm EST.
- “Comparison of the otoprotective profiles of antioxidant and anti-apoptotic compounds in ex vivo models of cisplatin-induced hearing loss” by Mathur et al, poster presentation on February 12 beginning at 1 pm EST.
- “Development of clinically relevant ex vivo models of cisplatin-induced hearing loss” by Uribe et al, poster presentation on February 12 beginning at 1 pm EST.
Additional presentations related to Otonomy’s other programs include:
- “Inner ear pharmacokinetics and tissue distribution of the sustained-exposure dexamethasone formulation Otividex™ in various species – predicting drug exposure in Meniere’s disease patients” by Piu et al, poster presentation on February 11 beginning at 1 pm EST.
- “Modified versions of NT-3 enable enhanced activation of TrkB and TrkC responses in ex vivo models relevant to cochlear synaptopathy” by Szobota et al, poster presentation on February 10 beginning at 1 pm EST.
- “Evaluation of rapid decalcification methods for histological assessment of rodent temporal bones” by Jones et al, poster presentation on February 9 beginning at 1 pm EST.